הבדלים בין גרסאות בדף "אפיניטור 2.5 מ"ג - Afinitor 2.5 mg"
מתוך ויקירפואה
שורה 8: | שורה 8: | ||
|התוויה= reatment of patients with advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib.* For the treatment of patients with SEGA associated with tuberous sclerosis (TS) who require therapeutic intervention but are not candidates for curative surgical resection.The effectiveness of Afinitor is based on an analysis of change in SEGA volume. Clinical benefit such as improvement in disease-related symptoms or increase in overall survival has not been demonstrated.* Treatment of progressive neuroendocrine tumors of pancreatic origin (PNET) in patients with unresectable, locally advanced or metastatic disease.The safety and effectiveness of AFINITOR® in the treatment of patients with carcinoid tumors have not been established.* For the treatment of hormone receptor – positive, HER2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence of progression follwing a non – steroidal aromatase inhibitor.* Afinitor ® is indicated for the treatment of adult patients with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery. The effectiveness of Afinitor in treatment of renal angiomyolipoma is based on an analysis of durable objective responses in patients treated for a median of 8.3 months. Further follow-up of patients is required to determine long-term outcomes. | |התוויה= reatment of patients with advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib.* For the treatment of patients with SEGA associated with tuberous sclerosis (TS) who require therapeutic intervention but are not candidates for curative surgical resection.The effectiveness of Afinitor is based on an analysis of change in SEGA volume. Clinical benefit such as improvement in disease-related symptoms or increase in overall survival has not been demonstrated.* Treatment of progressive neuroendocrine tumors of pancreatic origin (PNET) in patients with unresectable, locally advanced or metastatic disease.The safety and effectiveness of AFINITOR® in the treatment of patients with carcinoid tumors have not been established.* For the treatment of hormone receptor – positive, HER2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence of progression follwing a non – steroidal aromatase inhibitor.* Afinitor ® is indicated for the treatment of adult patients with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery. The effectiveness of Afinitor in treatment of renal angiomyolipoma is based on an analysis of durable objective responses in patients treated for a median of 8.3 months. Further follow-up of patients is required to determine long-term outcomes. | ||
|שם יצרן = [[NOVARTIS PHARMA STEIN AG, SWITZERLAND]] | |שם יצרן = [[NOVARTIS PHARMA STEIN AG, SWITZERLAND]] | ||
− | |שם בעל הרישום= NOVARTIS PHARMA SERVICES AG | + | |שם בעל הרישום= [[NOVARTIS PHARMA SERVICES AG]] |
|קישור למאגר משרד הבריאות1= {{מסחרי משרד הבריאות|Afinitor |אפיניטור}} | |קישור למאגר משרד הבריאות1= {{מסחרי משרד הבריאות|Afinitor |אפיניטור}} | ||
|עלון לרופא=[http://www.old.health.gov.il/units/pharmacy/trufot/alonim/Afinitor_DR_1384422956121.pdf "עלון לרופא באנגלית"], [http://www.old.health.gov.il/units/pharmacy/trufot/alonim/AFINITOR_11_2011_1322632030646.doc החמרה לעלון] , [http://www.old.health.gov.il/units/pharmacy/trufot/alonim/Afinitor_spc_pil_Feb_2013_1360494191961.doc החמרה לעלון] | |עלון לרופא=[http://www.old.health.gov.il/units/pharmacy/trufot/alonim/Afinitor_DR_1384422956121.pdf "עלון לרופא באנגלית"], [http://www.old.health.gov.il/units/pharmacy/trufot/alonim/AFINITOR_11_2011_1322632030646.doc החמרה לעלון] , [http://www.old.health.gov.il/units/pharmacy/trufot/alonim/Afinitor_spc_pil_Feb_2013_1360494191961.doc החמרה לעלון] |
גרסה מ־18:26, 6 בינואר 2014
נתוני הסל
נתוני הסל |
---|
הגבלות הסל
תרופה מוגבלת לרישום ע'י רופא מומחה או הגבלה אחרת |
התוויה בסל |
שימוש בסל |
תאריך הכללה בסל
03/01/2010 |
מסגרת הכללה בסל
טיפול בסרטן שד גרורתי לאחר טיפול אנדוקריני קודם, במשולב עם מעכב ארומטאז - הרחבת מסגרת ההכללה בסל - 2014 |
מינונים
התוויות נגד
תופעות לוואי
פרמקוקינטיקה
פרמקודינמיקה
תגובות בין-תרופתיות
שימוש בהיריון, הנקה
מאמרים
מידע ברשת
בעל הרישום NOVARTIS